The Health Ministry has revealed that faulty diagnostic kits from Roche, used to detect hormone receptors in breast and reproductive cancers, may have led to incorrect test results for up to 300 women. This flaw could mean some patients missed out on anti-hormonal therapies and instead received harsher treatments, such as chemotherapy. The affected test kits have been withdrawn, and all pathology labs have been instructed to review and, if necessary, retest samples from patients who may have been impacted. Health officials emphasize that patients will be contacted directly if their treatment recommendations change, and consultations with experts are ongoing to ensure no one is overlooked.